GlaxoSmithKline: cancer drug effective in study

(CercleFinance.com) - British drugmaker GlaxoSmithKline said that its experimental cancer drug dostarlimab has proved to be efficient in difficult-to-treat gastrointestinal cancers.


Data showed a 38.7% objective response rate (ORR) in patients with mismatch repair-deficient (dMMR) non-endometrial advanced solid cancers, who received the investigational monoclonal antibody, the company said.

Dostarlimab - which was discovered by AnaptysBio and Tesaro in 2014 - is now being developed by GSK.

A filing for approval is currently under review by the US Food and Drug Administration and the European Medicines Agency for the treatment of patients with endometrial cancer whose disease has progressed on or after chemotherapy.

Copyright (c) 2021 CercleFinance.com. All rights reserved.